ATE147409T1 - Verbindungen und verfahren zur behandlung thromboembolischer störungen - Google Patents

Verbindungen und verfahren zur behandlung thromboembolischer störungen

Info

Publication number
ATE147409T1
ATE147409T1 AT92305336T AT92305336T ATE147409T1 AT E147409 T1 ATE147409 T1 AT E147409T1 AT 92305336 T AT92305336 T AT 92305336T AT 92305336 T AT92305336 T AT 92305336T AT E147409 T1 ATE147409 T1 AT E147409T1
Authority
AT
Austria
Prior art keywords
thromboembolic disorders
methods
compounds
adducts
treating thromboembolic
Prior art date
Application number
AT92305336T
Other languages
English (en)
Inventor
Philip John Burck
Ronald Eugene Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE147409T1 publication Critical patent/ATE147409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT92305336T 1991-06-13 1992-06-11 Verbindungen und verfahren zur behandlung thromboembolischer störungen ATE147409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/714,537 US5272076A (en) 1991-06-13 1991-06-13 Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA

Publications (1)

Publication Number Publication Date
ATE147409T1 true ATE147409T1 (de) 1997-01-15

Family

ID=24870421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92305336T ATE147409T1 (de) 1991-06-13 1992-06-11 Verbindungen und verfahren zur behandlung thromboembolischer störungen

Country Status (9)

Country Link
US (1) US5272076A (de)
EP (1) EP0518652B1 (de)
JP (1) JPH05184365A (de)
AT (1) ATE147409T1 (de)
CA (1) CA2071145A1 (de)
DE (1) DE69216479T2 (de)
DK (1) DK0518652T3 (de)
ES (1) ES2096035T3 (de)
GR (1) GR3022779T3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8334499D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Derivatives
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
EP0293934B1 (de) * 1987-06-04 1994-08-31 Zymogenetics, Inc. Mutierter t-PA mit Kringle-Ersatz
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤

Also Published As

Publication number Publication date
JPH05184365A (ja) 1993-07-27
EP0518652B1 (de) 1997-01-08
US5272076A (en) 1993-12-21
ES2096035T3 (es) 1997-03-01
DK0518652T3 (da) 1997-06-30
DE69216479D1 (de) 1997-02-20
EP0518652A1 (de) 1992-12-16
DE69216479T2 (de) 1997-05-15
GR3022779T3 (en) 1997-06-30
CA2071145A1 (en) 1992-12-14

Similar Documents

Publication Publication Date Title
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
EP0471756A4 (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof
ATE85523T1 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
PT87294A (pt) Process for the preparation of 17beta-(cyclopropylamino)-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors and of pharmaceutical compositions containing the same
ATE121387T1 (de) Homologierte vitamin-d2-verbindungen und korrespondierende 1alpha-hydroxylierte verbindungen.
GR3015817T3 (en) Substituted alpha-amino acids having pharmaceutical activity.
ATE166354T1 (de) Azabicycloarylacetylen- und arylenynoxine als cholinergische mittel und verfahren zur behandlung
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE147409T1 (de) Verbindungen und verfahren zur behandlung thromboembolischer störungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
DE69109314D1 (de) Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee